Table 4 Association between anti-Ro52/TRIM21 antibodies and other SSc-related autoantibodies
From: Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis
Antibody | Prevalence (N = 963) | Anti-Ro52 antibody positive (n = 194) | Anti-Ro52 antibody negative (n = 769) | Pvalues | Mean anti-Ro52/TRIM21 titer (U/ml) | |||
|---|---|---|---|---|---|---|---|---|
| Â | n | % | n | % | n | % | Â | Â |
Centromere | 334 | 34.76% | 78 | 40.41% | 256 | 33.33% | NS | 1,098.64 |
Topoisomerase I | 150 | 15.58% | 19 | 9.79% | 131 | 17.04% | 0.0129 | 763.28 |
RNApolIII | 144 | 18.58% | 23 | 15.75% | 121 | 19.24% | NS | 1,164.47 |
Pm/Scl | 53 | 6.84% | 10 | 6.85% | 43 | 6.84% | NS | 1,381.13 |
U1 RNP | 59 | 6.13% | 20 | 10.31% | 39 | 5.07% | 0.0066 | 2,099.45 |
CENP-B | 285 | 35.58% | 64 | 42.95% | 221 | 33.90% | 0.0372 | 1,098.86 |
CENP-A | 275 | 34.33% | 61 | 40.94% | 214 | 32.82% | NS | 1,019.93 |
Ro60 | 53 | 5.50% | 40 | 20.62% | 13 | 1.69% | < 0.0001 | 5,530.66 |
SS-B/La | 26 | 2.70% | 18 | 9.28% | 8 | 1.04% | < 0.0001 | 6,003.88 |
Jo-1 | 6 | 0.62% | 4 | 2.06% | 2 | 0.26% | 0.0171 | 4,412.83 |
Sm | 39 | 4.05% | 13 | 6.70% | 26 | 3.38% | 0.0361 | 1,482.09 |
Ribosomal P | 14 | 1.45% | 3 | 1.55% | 11 | 1.43% | NS | 2,088.14 |
Chromatin | 44 | 4.57% | 10 | 5.15% | 34 | 4.42% | NS | 1,162.30 |